Artificial Saliva Market: Current Analysis and Forecast (2022-2028)

Chewing, swallowing, digesting, and speaking all depend on saliva. Additionally, it controls bacteria growth in the mouth & reducing the risk of infection and tooth decay. While primarily water, natural saliva also contains mucous, enzymes, and electrolytes. Although artificial saliva doesn't exactly like the saliva that our glands normally create, the combination of its ingredients can help relieve symptoms like bad breath and a feeling of dryness or stickiness in the mouth.

Also, doctors may recommend the use of artificial saliva alongside medications and medical treatments, such as pain medications and chemotherapy, that are known to cause dry mouth. For instance, according to the National Cancer Institute (NIH), in 2022, it is estimated that there are 18.1 million cancer survivors in the United States. This represents approximately 5.4% of the population and it is projected to increase by 24.4%, to 22.5 million, by 2032.

The artificial saliva market is expected to grow at a steady rate of around 13% owing to the increasing prevalence of dysphagia condition in cancer patients. Also, the expensive treatments for oral diseases in both developed & developing countries and the growing disposable income and increasing per-capita spending drive the growth of the market during the forecast period.

Based on product type, the market is segmented into oral spray, oral solution, oral liquid, gel, and powder. The oral spray category is to witness the highest CAGR during the forecast period. This is mainly due to their ease of use, efficiency & low cost, and these sprays are commonly used to treat dry mouth conditions. Also, increasing product development by key players drives the growth of the segment. For instance, Mouth Kote-MD, a mouth spray based on MycoDelens, a proprietary substance created and licensed by New Mexico Tech University, was presented by Parnell Pharmaceuticals, Inc. in 2021.

On the basis of age group, the market is bifurcated into adult and pediatric. Among these, the adult category dominated the growth of the artificial saliva market in 2020. This is mainly due to the artificial saliva being used more by adult patients and this is unlikely to change anytime soon as the dry mouth condition is typically more common in adult patients than pediatric ones.

The other factor for the growth of this segment is the growing dysphagia condition due to mouth cancer or oesophageal cancer. For instance, according to the World Cancer Research Fund (WCRF International), around 604,100 new cases of oesophageal cancer were diagnosed in 2020.

Based on distribution channel, the artificial saliva market has been classified into hospital pharmacies, retail pharmacies, supermarkets & hypermarkets, and others. The retail pharmacies category is to witness the highest growth during the forecast period. This is mainly due to the affordability of medicines and the growing population with rising cases of diabetes, stroke, Alzheimer's disease, Sjogren's syndrome, or HIV/AIDS which will cause dry mouth conditions. For instance, as per the International Diabetes Federation (IDF), around 1.2 million youngsters and youths have type 1 diabetes in 2021.

For a better understanding of the market adoption of the artificial saliva industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the availability of major market key players, rising awareness about oral diseases, growing product utilization to treat xerostomia, rising disposable incomes, increasing prevalence of cancer and Alzheimer's disease, growing technological advancements, and presence of a large patient population in the region, which is expected to aid the market growth. For instance, according to the National Center for Chronic Disease Prevention (CDC), in 2020, as many as 5.8 million Americans were living with Alzheimer's disease.

Some of the major players operating in the market include: GSK plc.; Cipla Inc.; Mission Pharmacal Company; Fresenius Kabi AG; Parnell Pharmaceuticals, Inc.; CCMed Ltd.; ENTOD INTERNATIONAL; Midatech Pharma PLC; Forward Science; Bausch Health Companies Inc.